Candel Therapeutics Targets Q4 2026 BLA for Prostate Cancer Drug, Initiates Pivotal NSCLC Phase 3, Secures Funding
CADL sits 22% above its 52-week low of $4.25.
Summary
Candel Therapeutics announced its fourth quarter and full year 2025 financial results alongside significant corporate highlights. The company is advancing its lead candidate, aglatimagene, towards a planned BLA submission for prostate cancer in Q4 2026 and is preparing to initiate a pivotal Phase 3 clinical trial in non-small cell lung cancer (NSCLC) in Q2 2026. Additionally, Candel received FDA clearance for its linoserpaturev IND in recurrent high-grade glioma. These clinical milestones are supported by recent strategic financing, including a term loan, a follow-on equity offering, and a royalty financing agreement, which significantly strengthens the company's balance sheet. This comprehensive update provides a clear and aggressive clinical development roadmap with multiple material catalysts throughout 2026, substantially de-risking the company's operational runway and future prospects. Investors should monitor the upcoming Q2 2026 Phase 3 prostate cancer data and the initiation of the NSCLC pivotal trial.
At the time of this announcement, CADL was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.6M. The 52-week trading range was $4.25 to $9.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.